太極集團(600129.SH)半年度淨利潤升64.07%至8910.41萬元
格隆匯8月15日丨太極集團(600129.SH)發佈2019年半年度報告，實現營業收入61.49億元，同比增長19.51%；歸屬於上市公司股東的淨利潤8910.41萬元，同比增長64.07%；歸屬於上市公司股東的扣除非經常性損益的淨利潤5362.61萬元，同比增長2.56%；基本每股收益0.16元。
報告期內，公司工業銷售收入33.76億元，比上年同期26.00億元增長29.83%。骨幹產品銷售增長較大的有：注射用頭孢唑肟鈉(益保世靈)含税銷售收入10.04億元，同比增長49%；洛芬待因緩釋片(思為普)含税銷售收入2.35億元，同比增長30.5%；天麻素注射液含税銷售收入1.72億元，同比增長24%；鹽酸託烷司瓊注射液含税銷售收入1.62億元，同比增長40%；小金片含税銷售收入1.39億元，同比增長25%；鹽酸嗎啡緩釋片(美菲康)含税銷售收入8171萬元，同比增長8%；複方甘草片含税銷售收入7200萬元，同比增長80%；六味地黃丸含税銷售收入5509萬元，同比增長24%；沉香化氣片含税銷售收入3900萬元，同比增長36%。
積極推進公司產品參與國際市場競爭，報告期內，涪陵藥廠的藿香正氣口服液在俄羅斯、老撾、加拿大、莫桑比克獲得註冊；重慶中藥二廠六味地黃丸獲得香港註冊；西南藥業首批軟袋輸液出口菲律賓，實現了化學藥海外銷售零的突破。
報告期內，公司實現商業銷售收入26.02億元，比上年同期24.17億元增長7.66%。全面提升桐君閣大藥房的價格競爭力、產品規劃和服務質量，全面利用會員系統，進行分病類精準營銷，增強會員粘性。繼續推進智能化管理，實行遠程監督，提升內部管理水平，試點智能補貨系統，降低成本。繼續實施川渝大商業“113”戰略，重慶市23個區縣聯合體醫院已完成全部開户。多渠道與國內外廠家接洽，積極引進西藥治療性品種，改善品種結構，提高在醫療機構的配送權。藉助藿香正氣口服液有序營銷體系，加速川渝三終端網絡建設，提高對診所、社會藥房和加盟藥房的直接配送比例。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
